Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol‑related liver disease represent distinct clinical phenotypes and fibrosis risks: insights from a population-based Polish cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Péan de Ponfilly-Sotier Marie, Jachiet Vincent, Benhamou Ygal, Lahuna Constance, De Renzis Benoit, Kottler Diane, Voillat Laurent, Dimicoli-Salazar Sophie, Banos Anne, Chauveheid Marie-Paule, Alexandra Jean-François, Grignano Eric, Liferman François, Laborde Mathilde, Broner Jonathan, Michel Marc, Lambotte Olivier, Laribi Kamel, Venon Marie-Dominique, Dussol Bertrand, Martis Nihal, Thepot Sylvain, Park Sophie, Couret David, Roux-Sauvat Marielle, Terriou Louis, Hachulla Eric, Bally Cécile, Galland Joris, Allain Jean-Sébastien, Parcelier Anne, Peterlin Pierre, Cohen-Bittan Judith, Regent Alexis, Ackermann Felix, Le Guen Julien, Algrin Caroline, Charles Pierre, Daguindau Etienne, Puechal Xavier, Dunogue Bertrand, Blanchard-Delaunay Claire, Beyne-Rauzy Odile, Grobost Vincent, Schmidt Jean, Le Gallou Thomas, Dubos-Lascu Georgeta, Sonet Anne, Denis Guillaume, Roy-Peaud Frédérique, Fenaux Pierre, Adès Lionel, Fain Olivier, Mekinian Arsène, MINHEMON (French Network of Dysimmune Disorders Associated wit Hemopathies) and GFM
Аннотация
OBJECTIVES: This study aimed to assess the prevalence, clinical profiles, and liver fibrosis burden of MASLD and MetALD in a representative population from Central and Eastern Europe.
PATIENTS AND METHODS: This study is part of the Bialystok PLUS (Polish Longitudinal University Study), an ongoing, prospective population‑based cohort study. A random sample of 2456 adult residents of the city of Białystok, Poland, was analyzed. Anthropometric, epidemiologic, clinical, and lifestyle‑related parameters were assessed. The participants were categorized into the MASLD, MetALD, and control groups. Differences in metabolic comorbidities and liver fibrosis severity were evaluated in each cohort.
RESULTS: The prevalence of MASLD was 22.72%, while MetALD accounted for 2.08% of the population. MASLD was predominantly associated with obesity and diabetes mellitus, whereas MetALD showed a higher prevalence of arterial hypertension and dyslipidemia. Significant liver fibrosis was more frequent in MetALD (17.8%) and MASLD (15.6%), as compared with the controls (5.1%; P <0.001 and P = 0.005, respectively). The highest cirrhosis rates were observed in 4.44% of the MetALD participants, 0.58% of the MASLD patients, and 0.12% of the controls (P = 0.001). Risk factors for significant fibrosis were analyzed across all groups.
CONCLUSIONS: MASLD and MetALD represent a substantial and distinct health burden not only in the Polish population but likely across Central and Eastern Europe, given shared epidemiologic patterns of metabolic dysfunction and similar alcohol consumption. Understanding the interplay between these factors is crucial for improving diagnosis establishment, treatment strategies, and public health policies in this region.